To address the drawbacks of TGF-β inhibitors in clinical trials with poor pharmacokinetic behavior and high systemic toxicity with insufficient tumor permeability, Park and co-workers developed a novel nanoparticle for the co-delivery of TGF-β inhibitor and interleukin-2. Here, IL2 is linked to neoplasm.